A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

NCT04272775 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

14

Enrollment

INDUSTRY

Sponsor class

Stopped Business Decision; No Safety Or Efficacy Concerns

Conditions

Relapsed and/or Refractory Multiple Myeloma

Interventions

DRUG: Ixazomib
DRUG: Lenalidomide
DRUG: Dexamethasone

Sponsor

Takeda